Insiders Buy the Holdings of XBI ETF

A look at the weighted underlying holdings of the SPDR S&P Biotech ETF (XBI) shows an impressive 13.5% of holdings on a weighted basis have experienced insider buying within the past six months.

START SLIDESHOW:
10 ETFs With Stocks That Insiders Are Buying »

Repligen Corp. ( RGEN), which makes up 1.62% of the SPDR S&P Biotech ETF (XBI), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $17,166,976 worth of RGEN, making it the #5 largest holding. The table below details the recent insider buying activity observed at RGEN:

RGEN — last trade: $15.66 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
04/15/2014 James R. Rusche Senior Vice President 25,000 $3.05 $76,250.00
04/15/2014 Daniel P. Witt Senior Vice President 10,000 $3.05 $30,500.00

And Merrimack Pharmaceuticals Inc. ( MACK), the #37 largest holding among components of the SPDR S&P Biotech ETF (XBI), shows 7 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $13,372,038 worth of MACK, which represents approximately 1.26% of the ETF's total assets at last check. The recent insider buying activity observed at MACK is detailed in the table below:

MACK — last trade: $4.76 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
11/29/2013 Michael E. Porter Director 75,000 $3.60 $270,185.00
11/29/2013 William M. McClements SVP of Corporate Operations 7,000 $3.61 $25,255.00
11/27/2013 Gary L. Crocker Director 207,000 $3.72 $769,536.30
11/29/2013 Anthony J. Sinskey Director 3,800 $3.92 $14,877.00
12/03/2013 Michael E. Porter Director 75,000 $4.17 $312,907.50
12/02/2013 William M. McClements SVP of Corporate Operations 2,000 $4.06 $8,119.20
12/03/2013 Sarah E. Nash Director 47,500 $4.17 $198,306.00
12/04/2013 Robert J. Mulroy President and CEO 33,100 $4.42 $146,225.87
12/06/2013 James H. Quigley Director 39,000 $4.70 $183,257.10
12/10/2013 Michael E. Porter Director 18,000 $4.38 $78,840.00
12/12/2013 William M. McClements SVP of Corporate Operations 4,000 $4.26 $17,059.20
12/17/2013 Michael E. Porter Director 25,000 $4.75 $118,811.25

If you liked this article you might like

Drug Stocks Find Trump Animus a Bitter Pill

Drug Stocks Find Trump Animus a Bitter Pill

5 Health Care Stocks Set to Bounce

5 Health Care Stocks Set to Bounce

Repligen Has More Upside Ahead

Repligen Has More Upside Ahead

Trade-Ideas: Repligen (RGEN) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Repligen (RGEN) Is Today's Weak On High Relative Volume Stock

Today's Dead Cat Bounce Stock Is Repligen (RGEN)

Today's Dead Cat Bounce Stock Is Repligen (RGEN)